QureGenAI Selected as the Sole Innovative Biopharma Company in China's Top 10 Quantum Computing Application Cases of 2025, Marking Transition from Research to Industrial Deployment

Recently, at the 2nd Quantum Annual Conference hosted by Photon Box, the results of the 2025 "Quantum10 China Quantum Company Top Ten Innovative Use Cases" were officially announced. AceMapAI was recognized for "Benchmark Framework for Real Drug Molecule Discovery with Quantum-Classical CollaborationSuccessfully selected.

Notably, under the strategic guidance of the "15th Five-Year Plan," quantum technology, as a core track of future industries, is becoming a key driving force for technological transformation and industrial upgrading. Among the ten selected companies,AceMapAI is the only enterprise from the biopharmaceutical field and has successfully implemented the first 15-qubit superconducting quantum computer in Northwest China. It is also the only company that owns a quantum computer and applies it to innovative drug research and development.This result also means that the industrial application value of quantum computing technology in the fields of life sciences and innovative drug research and development is gradually gaining attention at the industry level.

Figure: The First Quantum Computer in Western China

"Quantum10 China's Top Ten Innovative Paradigm Use Cases of Quantum Companies" was initiated by QuantumChina, a quantum technology industry media. The selection focuses on technological breakthroughs and industrial implementation in real scenarios within China's quantum industry. The review scope covers multiple fields such as quantum computing, quantum communication, and quantum measurement, aiming to identify benchmark cases that represent the application and innovation capabilities of China's quantum industry.

The selection process involves multiple rounds of screening, including expert reviews and industry voting, with a focus on technological innovation, industrial application value, and commercial implementation potential. The selected cases for this year are mainly concentrated in areas such as quantum computing infrastructure, quantum algorithm platforms, and industry application exploration.

Against this background,AceMapAI's selection represents the exploration of quantum computing applications in the real industrial scenario of innovative drug research and development.

AceMapAI is the world’s first innovative drug R&D company driven by quantum computing and AI technology (Quantum AIDD), with a primary business model centered on pipeline License delivery and operation. Unlike many quantum computing enterprises, AceMapAI has explored the application pathways of quantum computing in drug design from the outset, starting with the real industry needs of innovative drug R&D.

This exploration spans two technological systems: quantum computing and biomedicine, attempting to truly embed the capabilities of quantum algorithms into the drug development process.

Biopharmaceutical R&D essentially relies on the precise calculation and simulation of molecular electronic structures, which is precisely one of the most advantageous application directions of quantum computing in theory.However, in the current NISQ (Noisy Intermediate-Scale Quantum) era, the scale of quantum hardware and noise issues still limit its direct application in real drug systems.

How to make quantum computing truly serve the drug discovery process under the condition of limited quantum resources has become a key issue that the industry needs to solve.

In response to this issue, AceMapAI, in collaboration with China Pharmaceutical University and the "Chaos Universe" lab of Mobile Cloud, has built the world's first Quantum AIDD Benchmark for real drug molecules.

Figure: AceMapAI published a systematic research work on quantum drug discovery on the arXiv preprint platform

The core goal of this framework is to establish a standardized method for systematically evaluating the practical capabilities of quantum computing in drug discovery. The research team conducted systematic tests on real drug-related molecular systems based on active space selection strategies, and through the collaborative evaluation of quantum algorithms and classical computing, constructed a complete computational workflow and evaluation index system.

TyonQ GitHub Address:https://github.com/QureGenAI-Biotech/TyxonQ

In the research, the team also completed key experiments on a real superconducting quantum chip (QPU). The results show that, under current hardware conditions, hybrid quantum algorithms like VQE can already achieve computationally reasonable chemical results on real devices through appropriate active space selection and algorithm design.

This work establishes an important technical "benchmark" for the application of quantum computing in the field of drug research and development, and also provides a data foundation for the future collaborative optimization of quantum algorithms and hardware.

The completion of this research work also离不开 the support of industrial ecosystem partners. Among them, China Mobile Cloud's "Chaos Universe" laboratory provided critical computing power and hardware resource support, enabling the relevant algorithms to be experimentally validated on real quantum computing devices.

At the same time, AceMapAI joined hands with Chang'an Pioneer to build the Pioneer AceMapAI Quantum AI Fusion Computing Center, achieving the delivery and application practice of the first superconducting quantum computer in Northwest China, further promoting the implementation of quantum computing power in life science scenarios.

The development of the quantum computing industry is, in itself, a process of collaborative evolution among hardware, algorithms, and application scenarios. Starting from the needs of innovative drug research and development, AceMapAI is working with computational power infrastructure partners to promote the exploration of quantum computing applications in the life sciences field, providing a new practical path for industrial collaborative innovation.

Based on the above research results, AceMapAI is advancing the construction of the Quantum AIDD technology system.AceMapAI's self-developed quantum + AI drug design platform "Crayfish" QureGenAI has entered internal testing in March 2026, providing support for the entire process of innovative drug research and development.InWhole Proteomics Analysis, Off-target Prediction, Toxicity Prediction, Seamless Integration of Quantum ChemistryCore functions such as... Currently, the company has successfully advanced 2 R&D pipelines into the Pre-IND stage and 4 pipelines to the PCC stage., fully verifying the practical feasibility of the Quantum AIDD paradigm in innovative drug development.

The selection of "Quantum10 China Quantum Company Top Ten Innovative Paradigm Use Cases" also marks that the exploration of quantum computing applications in the biopharmaceutical field has begun to gain attention and recognition at the industry level.

In the future, with the continuous improvement of quantum hardware capabilities and the algorithm system, Quantum AIDD is expected to drive innovative drug research and development from the traditional "trial and error based on experience" towards a more rational and predictable molecular design model.